FDA Approves Oral Topotecan for Relapsed Small-Cell Lung Cancer
FDA Approves Oral Topotecan for Relapsed Small-Cell Lung Cancer
The US Food and Drug Administration (FDA) has approved oral topotecan (Hycamtin) capsules for the treatment of relapsed small-cell lung cancer (SCLC). Topotecan capsules are indicated for patients who had a complete or partial response to first-line chemotherapy and who are at least 45 days from the end of that treatment. Topotecan capsules are the only oral single-agent chemotherapy approved for the treatment of SCLC after failure of first-line therapy. The product will be available in 2008.
Articles in this issue
Ixabepilone Approved for the Treatment of Advanced Breast Cancer
Positive Results Announced From Pivotal Study of Bendamustine in Non-Hodgkin's Lymphoma
ASCO/ASH Release Updated Guidelines on Chemotherapy-Related Anemia Treatments
Spending More for Lung Cancer Treatment Did Not Substantially Increase Patients' Lives
FDA Approves Oral Topotecan for Relapsed Small-Cell Lung Cancer
Temsirolimus Improves Survival in Renal Cell Carcinoma Patients
Breast MRI: The Radiologist's Perspective
Continued Progress in Treatment Options for Multiple Myeloma: From Past to Present and Future
Dermatologic Issues in Cancer Patients: Review of a Review
The Three Most Common Chemotherapy-Related Skin Reactions
Anthracyclines Survive Targeted Therapy
Reducing the Burden of Cancer
Prostate Cancer, PSA, and Questions That Can Only Be Answered By Clinical Trials
Biochemical Failure in Prostate Cancer: Managing Patients with Limited Data
Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
